US and Bengaluru based Biopharma startup Bugworks has secured $7.5 million in a funding round led by University of Tokyo Edge Capital. Other investors including Global Brain Corporation Japan and Acquipharma Holdings also participated. The latest capital would be infused by the company towards completing its phase-1 studies for GYROX series intravenous drug candidate.
Launched in 2014, Biopharma is a platform that is focused on designing broad-spectrum antibiotics. Previously, the company had raised $9 million in a Series A round from 3one4 and others in 2018. (Source)